| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Correspondence |
N-phenylanthranilic acid (NPAA) has been used as an inducer of nephropathy and RPN in the rat, causing similar pathology to that seen in human analgesic abusers [57]. This study investigated the correlation between histopathology of NPAA induced nephropathy in rats and its ex vivo MRI appearance.
12 male Han/Wistar rats (Charles River, UK) were used. The age at the start of dosing was 68 weeks. Animals were housed four to a cage with water from the site drinking supply and pelleted diet. Eight animals were dosed once daily, by oral gavage, of NPAA 700 mg kg1, for 14 days. Four animals were treated with vehicle (1.25%(w/v) carboxymethyl cellulose in water). All animals were euthanized by halothane overdose prior to necropsy approximately 24 h after receiving the final dose. MRI was performed immediately following euthanasia. Without other intervention, left kidney was removed and placed in a small vial containing 10% formalin. These kidneys were scanned using a Varian horizontal 9.4 T magnet (Varian, Palo Alto, CA; 40 Gauss cm1 gradient strength; rise time 200 µs), and a 38 mm quadrature birdcage radiofrequency (RF) coil. Kidneys were positioned with their longitudinal axis parallel to B0. MRI included a transverse spin echo multiple slice sequence (repetition time (TR)/echo time (TE) = 1000/13 ms, resolution = 0.078 mm x 0.313 mm), a coronal spin echo multiple slice sequence (TR/TE = 2000/30 ms, resolution = 0.313 mm x 0.313 mm), and a coronal gradient echo multiple slice sequence (TR/TE = 35/6 ms, flip angle = 40°, resolution = 0.313 mm x 0.313 mm). The slice thickness was 0.5 mm for all scans. After the MRI scan, kidneys were processed to haematoxylin-eosin stained sections plus immunohistochemistry for collecting ducts. All procedures were performed in full compliance with licenses issued under the UK Animals (Scientific Procedures) act, 1986.
Histopathology revealed that kidneys of all NPAA treated animals showed various nephropathy changes; these kidneys were also large in size. Microscopically, NPAA induced nephropathy included cortical collecting tubular dilatation, tubular basophilia, corticomedullary interstitial nephritis, intratubular protein casts and papillary collecting tubule dilation. One rat showed a minimal degree of unilateral renal papilla necrosis.
With MRI, the medulla of control animal kidneys showed higher signal than the cortex both on spin echo and gradient echo images, with a clear corticomedullary junction (
Figures 1a and 2a
). In kidneys with NPAA induced nephropathy, a loss in the clear demarcation of the corticomedullary junction was seen (
Figures 1b,c and 2b
). Additionally, fine radial bands pointing to the renal papilla with alternating high and low signal were observed primarily in the cortex. These radial bands were aligned with the medulla rays seen longitudinally (Figure 1b,c
). These pathological changes could be observed on both spin echo images and gradient echo images, although spin echo images tended to show richer tissue contrast than gradient echo images with the pulse sequence parameters used. MRI also revealed an increase in overall dimensions of kidney compared with the control kidneys.
|
|
With the magnetic field and gradient strength used in this study, higher spatial resolution could be achieved. However, this was constrained during the study by the requirement that the MR scan duration needed to be minimized so that the kidney specimens could be processed quickly for further histology. In addition, our results are from ex vivo study with the kidney not being perfused. Further in vivo study is needed to confirm these findings.
In conclusion, our ex vivo MRI preliminary results appear to suggest that non-contrast-enhanced MRI could provide sensitive imaging markers for NPAA induced kidney damage. These findings could potentially be translated to non-invasive in vivo animal studies and clinical studies in humans.
AstraZeneca Pharmaceuticals Alderley Park Macclesfield Cheshire UK
Received for publication February 15, 2006. Revision received August 16, 2006. Accepted for publication August 25, 2006.
References
This article has been cited by other articles:
![]() |
Y.-X. J Wang and S.-X. Yan Biomedical imaging in the safety evaluation of new drugs Lab Anim, October 1, 2008; 42(4): 433 - 441. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| BJR | DMFR | IMAGING | ALL BIR JOURNALS |